TRUDHESA

Peak

dihydroergotamine mesylate

NDANASALSPRAY, METERED

Approved

Sep 2021

Lifecycle

Peak

Competitive Pressure

0/100

Clinical Trials

1

Clinical Trials (1)

NCT01089062Phase 1Completed

Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (DHE) on Pulmonary Arterial Pressure

Started Mar 2010

24 enrolled

Healthy

Loss of Exclusivity

LOE Date

Jan 4, 2039

156 months away

Patent Expiry

Jan 4, 2039

Patent Records (5)

Patent #	Expiry	Type	Use Code
9550036	Sep 5, 2032	Product	—
10507295	Dec 25, 2032	Product	—
10940278	Jan 23, 2033	Product	—
9919117	Mar 17, 2033	Product	U-3218
11266799	Nov 5, 2036	Product	—

External Resources

Full prescribing information

FDA approval history

Drug nomenclature & identifiers